Verrica Pharmaceuticals (VRCA) Earnings Analysis
Verrica Pharmaceuticals (VRCA) next reports earnings on 2026-08-11, consensus EPS -0.41 USD. Last quarter (2026-03-11) it missed with EPS -0.56 USD vs -0.43 USD est (-30.2%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -3.66.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does VRCA next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.41 USD |
| Revenue estimate | 0.01B |
VRCA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-11 | -0.56 USD | -0.43 USD | -30.2% | Miss |
| 2025-11-14 | 0.13 USD | -1.14 USD | +111.4% | Beat |
| 2025-03-11 | -0.24 USD | -0.25 USD | +4% | Beat |
| 2024-11-04 | -0.49 USD | -0.37 USD | -32.4% | Miss |
| 2024-08-14 | -0.31 USD | -0.43 USD | +27.9% | Beat |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
VRCA valuation and analyst view
| Trailing P/E | -3.66 |
|---|---|
| Trailing EPS | -1.67343 USD |
| Price / book | 3.78 |
| Dividend yield | 0.00% |
| Market cap | 0.06B |
| Analyst consensus | Buy (6 buy / 4 hold / 0 sell) |
| Avg price target | 17 USD |
Related research pages
Frequently asked questions
When is Verrica Pharmaceuticals (VRCA)'s next earnings date?
Verrica Pharmaceuticals is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.41 USD and revenue estimate of 0.01B.
Did VRCA beat earnings last quarter?
In its 2026-03-11 report, VRCA posted EPS of -0.56 USD versus a -0.43 USD estimate — a miss of 30.2%.
What is VRCA's earnings track record?
Over the last 5 reported quarters with consensus data, VRCA beat estimates 3 times (60%).
What is VRCA's current P/E ratio and EPS?
VRCA trades at a trailing P/E of -3.66 on trailing EPS of -1.673430890993523 USD.
What do analysts rate VRCA?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.